The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 09, 2018

Filed:

Jun. 10, 2015
Applicant:

Gilead Sciences, Inc., Foster City, CA (US);

Inventors:

Shaopei Cai, Seattle, WA (US);

Zhimin Du, Belmont, CA (US);

Joshua Kaplan, Foster City, CA (US);

Jennifer A. Loyer-Drew, Seattle, WA (US);

Devan Naduthambi, San Bruno, CA (US);

Barton W. Phillips, San Mateo, CA (US);

Gary Phillips, Issaquah, WA (US);

Joshua Van Veldhuizen, Seattle, WA (US);

William J. Watkins, Saratoga, CA (US);

Suet Chung Yeung, Redmond, WA (US);

Assignee:

Gilead Sciences, Inc., Foster City, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); C07D 239/04 (2006.01); C07D 239/80 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 407/14 (2006.01); C07D 487/04 (2006.01); C07D 239/90 (2006.01); C07D 471/04 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); C07D 239/04 (2013.01); C07D 239/80 (2013.01); C07D 239/90 (2013.01); C07D 401/14 (2013.01); C07D 407/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01);
Abstract

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.


Find Patent Forward Citations

Loading…